Epileptic Seizures Treatment Market Size, Share, Trends, Growth, Consumption, Revenue, Company Analysis and Forecast 2021-2027

According to Vision Research Reports, the global epileptic seizures treatment market size surpassed at US$ 1.3 Bn in 2019 and to reach US$ 1.7 billion by 2027.

The global epileptic seizures treatment market is expected to grow at a moderate CAGR of 4.1 % over the forecast period 2020 to 2027. Increasing prevalence of epileptic seizures in patients worldwide, focus on providing a seizure-free life to patients, entry of a number of seizure detection devices, advancements in technology, and focus on research and development. Market players should focus on improving the efficacy of existing treatments and improving the accessibility to current epileptic seizures treatments particularly in developing regions.

In epilepsy, the brain activity becomes abnormal, resulting in recurrent seizures that are short episodes of involuntary movement, which may involve a part of the body or the entire body. These seizures in some cases cause loss of consciousness and bladder function, or bowel control. An epileptic seizure is defined as a period of symptoms due to abnormally excessive or synchronous neuronal activity in the brain. Treatment for epileptic seizures include benzodiazepines, phenytoin, and dosphenytoin. Benzodiazepines are first-line treatment for status epilepticus and repetitive seizures due to better efficacy and quicker action.

Drivers

  • Rise in prevalence of status epilepticus and acute repetitive seizures is the major factor boosting the growth of the global epileptic seizures treatment market
  • Introduction of novel drug treatments and route of administration for epileptic seizures fuels the growth of the global epileptic seizures treatment market
  • For instance, in January 2020, the U.S. FDA approved Neurilis, Inc.’s Valtoco (diazepam nasal spray) in the U.S. This is a new seizure medicine designed to treat periods of frequent seizures or cluster seizures.
  • Moreover, genetic factors associated with brain malformations & epileptic seizures, and increase in incidence of cardiovascular diseases, head injuries, brain cancer, infections, and substance abuse are the other factors accelerating the growth of the global epileptic seizures treatment market

Rise in Prevalence of Epilepsy with Increase in Status Epilepticus & Repetitive Seizures to Drive Global Market

Increase in patient population with status epilepticus and acute repetitive seizures is the major factor fueling the growth of the global epileptic seizures treatment market. According to the World Health Organization (WHO), epilepsy accounts for a considerable proportion of the world’s disease burden; globally, more than 50 million people are affected by this disease. The introduction of novel drug treatments and routes of administration for epileptic seizures and genetic factors associated with brain malformations & epileptic seizures are other factors accelerating the growth of the global epileptic seizures treatment market. Moreover, increase in incidence of cardiovascular diseases, head injuries, brain cancer, infections, and substance abuse drives the global epileptic seizures treatment market.

Diazepam to be Lucrative Segment

In terms of therapeutic, the global epileptic seizures treatment market has been classified into midazolam, alprazolam, diazepam, lorazepam, phenytoin, fosphenytoin, and others. The lorazepam segment dominated the global market in 2019 owing to quick action, long lasting effect, large number of lorazepam prescriptions, and patient preference for oral route. Diazepam is likely to be a promising segment during the forecast period. New route of administration, strategic collaboration between companies for development & commercialization of diazepam, and lower prescription cost for diazepam are the major factors attributed to the higher growth of the diazepam segment.

Status Epilepticus to Dominate Market

Based on type, the global epileptic seizures treatment market has been categorized into repetitive seizures, status epilepticus, and others. The status epilepticus segment accounted for major market share in 2019, owing to rise in number of patients with status epilepticus, pipeline products, new route of administration with better effective ways for the treatment, and rise in awareness about status epilepticus treatment. The status epilepticus segment has been bifurcated into convulsive status epilepticus and non-convulsive status epilepticus.

Nasal to be Preferred Route of Administration

In terms of route of administration, the global epileptic seizures treatment market has been divided into oral/buccal, rectal, nasal, and parenteral. The oral/buccal segment dominated the global epileptic seizures treatment market in 2019. The trend is expected to continue from 2020 to 2030 owing to patient convenience with oral route, approval & launch of buccal film medications, availability of a large number of products that can be administered through oral route, and new products with better patient compliance. Nasal is likely to be a highly lucrative segment during the forecast period. The segment is projected to expand at a higher CAGR during the forecast period due to new drug approval, better penetration among patients due to convenient route, and better tolerability.

Retail Pharmacies to Hold Major Market Share

Based on distribution channel, the global epileptic seizures treatment market has been segregated into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment accounted for major share of the global market in 2019 due to easy availability of branded as well as generic drugs, increase in number of pharmacy retail chain stores, and joint ventures & strategic collaboration partnerships between retail pharmacy giants.

Regional Overview

  • In terms of region, the global epileptic seizures treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
  • North America dominated the global epileptic seizures treatment market in 2019, and the trend is projected to continue during the forecast period
  • The current and future sizes of the epileptic seizures treatment market, in terms of value (US$ Mn), of regional markets and their major countries have been provided in the report for the period from 2018 to 2030, along with their CAGRs for the period from 2020 to 2030
  • The study also offers a list of recommendations, highlights, and useful insights of the market, which would help new companies willing to enter the market and existing companies to increase market shares and help in the decision-making process

Competition Landscape

The global epileptic seizures treatment market is fragmented in terms of number of players, with entry of several new players. Key players in the global market include Bausch Health Companies, Inc., GlaxoSmithKline plc., UCB S.A., Pfizer, Inc., Apotex, Inc., Alexza Pharmaceuticals, Inc., Neurelis, Inc., and Veriton Pharma. New product development with new route of administration, mergers, acquisitions & strategic collaborations, distribution tie-ups, and increased research & development expenditure are the major strategies adopted by leading companies in the global epileptic seizures treatment market.

Market Segmentation

By Therapeutic

    • Midazolam
    • Alprazolam
    • Diazepam
    • Lorazepam
    • Phenytoin
    • Fosphenytoin
    • Others

By Type

  • Repetitive Seizures
  • Status Epilepticus
    • Convulsive Status Epilepticus
    • Non-convulsive Status Epilepticus
  • Others

By Route of Administration

  • Oral/Buccal
  • Rectal
  • Nasal
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific          
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Scope of the Report

VRR’s report on the global epileptic seizures treatment market studies the past as well as current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2020 to 2030. The report provides the overall market revenue of the global epileptic seizures treatment market for the period 2018–2030, considering 2020 as the base year and 2030 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global epileptic seizures treatment market for the forecast period.

The report has been prepared after extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global epileptic seizures treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomena in the global epileptic seizures treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Furthermore, the report sheds light on changing competitive dynamics in the global epileptic seizures treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global epileptic seizures treatment market.

The report delves into the competition landscape of the global epileptic seizures treatment market. Key players operating in the global epileptic seizures treatment market have been identified, and each one of them has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global epileptic seizures treatment market that have been profiled in this report.

Key Questions Answered in Epileptic Seizures Treatment Market Report

  1. What is the sales/revenue generated by each therapeutic, type, route of administration, and distribution channel segment of the global epileptic seizures treatment market across all regions during the forecast period?
  2. What are the opportunities in the global epileptic seizures treatment market?
  3. What are the major drivers, restraints, opportunities, and threats in the market?
  4. Which region is likely to expand at the fastest CAGR during the forecast period?
  5. Which epileptic seizures treatment segments are expected to generate the highest revenue globally in 2030? Which segment is projected to expand at the highest CAGR during the forecast period?
  6. What is the market share or position of different companies operating in the global market in 2019?

Research Objectives and Research Approach

The comprehensive report on the global epileptic seizures treatment market begins with an overview of the market, followed by the scope and objectives of this study. Following this, the report provides detailed explanation of the objectives behind this study, pipeline analysis, disease prevalence in key countries, key industry events, and impact of COVID-19 in global epileptic seizures treatment market have been provided.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into small ones. The entire report comprises an exhaustive collection of graphs and tables appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global epileptic seizures treatment market in terms of therapeutic, type, route of administration, distribution channel, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2030 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global epileptic seizures treatment market.

Table of Contents

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Epileptic Seizures Treatment Market

4. Market Overview

4.1. Introduction

4.1.1. Market Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Epileptic Seizures Treatment Market Analysis and Forecast, 2018–2027

4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

5.1. Pipeline Analysis

5.2. Disease Prevalence & Incidence Rate globally with key countries

5.3. Key Industry Events (mergers, acquisitions, collaborations, partnerships, etc.)

5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

6. Global Epileptic Seizures Treatment Market Analysis and Forecast, by Therapeutics

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Market Value Forecast, by Therapeutics, 2018–2027

6.3.1. Midazolam

6.3.2. Alprazolam

6.3.3. Diazepam

6.3.4. Lorazepam

6.3.5. Phenytoin

6.3.6. Fosphenytoin

6.3.7. Others

6.4. Market Attractiveness Analysis, by Therapeutics

7. Global Epileptic Seizures Treatment Market Analysis and Forecast, by Type

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Market Value Forecast, by Type, 2018–2027

7.3.1. Repetitive Seizures

7.3.2. Status Epilepticus

7.3.2.1. Convulsive Status Epilepticus

7.3.2.2. Non-convulsive Status Epilepticus

7.3.3. Others

7.4. Market Attractiveness Analysis, by Type

8. Global Epileptic Seizures Treatment Market Analysis and Forecast, by Route of Administration

8.1. Introduction & Definition

8.2. Key Findings / Developments

8.3. Market Value Forecast, by Route of Administration, 2018–2027

8.3.1. Oral/Buccal

8.3.2. Rectal

8.3.3. Nasal

8.3.4. Parenteral

8.4. Market Attractiveness Analysis, by Route of Administration

9. Global Epileptic Seizures Treatment Market Analysis and Forecast, by Distribution Channel

9.1. Introduction & Definition

9.2. Key Findings / Developments

9.3. Market Value Forecast, by Distribution Channel, 2018–2027

9.3.1. Hospital Pharmacies

9.3.2. Retail Pharmacies

9.3.3. Online Pharmacies

9.4. Market Attractiveness Analysis, by Distribution Channel

10. Global Epileptic Seizures Treatment Market Analysis and Forecast, by Region

10.1. Key Findings

10.2. Market Value Forecast, by Region

10.2.1. North America

10.2.2. Europe

10.2.3. Asia Pacific

10.2.4. Latin America

10.2.5. Middle East & Africa

10.3. Market Attractiveness Analysis, by Country/Region

11. North America Epileptic Seizures Treatment Market Analysis and Forecast

11.1. Introduction

11.1.1. Key Findings

11.2. Market Value Forecast, by Therapeutics, 2018–2027

11.2.1. Midazolam

11.2.2. Alprazolam

11.2.3. Diazepam

11.2.4. Lorazepam

11.2.5. Phenytoin

11.2.6. Fosphenytoin

11.2.7. Others

11.3. Market Value Forecast, by Type, 2018–2027

11.3.1. Repetitive Seizures

11.3.2. Status Epilepticus

11.3.2.1. Convulsive Status Epilepticus

11.3.2.2. Non-convulsive Status Epilepticus

11.3.3. Others

11.4. Market Value Forecast, by Route of Administration, 2018–2027

11.4.1. Oral/Buccal

11.4.2. Rectal

11.4.3. Nasal

11.4.4. Parenteral

11.5. Market Value Forecast, by Distribution Channel, 2018–2027

11.5.1. Hospital Pharmacies

11.5.2. Retail Pharmacies

11.5.3. Online Pharmacies

11.6. Market Value Forecast, by Country, 2018–2027

11.6.1. U.S.

11.6.2. Canada

11.7. Market Attractiveness Analysis

11.7.1. By Therapeutics

11.7.2. By Type

11.7.3. By Route of Administration

11.7.4. By Distribution Channel

11.7.5. By Country

12. Europe Epileptic Seizures Treatment Market Analysis and Forecast

12.1. Introduction

12.1.1. Key Findings

12.2. Market Value Forecast, by Therapeutics, 2018–2027

12.2.1. Midazolam

12.2.2. Alprazolam

12.2.3. Diazepam

12.2.4. Lorazepam

12.2.5. Phenytoin

12.2.6. Fosphenytoin

12.2.7. Others

12.3. Market Value Forecast, by Type, 2018–2027

12.3.1. Repetitive Seizures

12.3.2. Status Epilepticus

12.3.2.1. Convulsive Status Epilepticus

12.3.2.2. Non-convulsive Status Epilepticus

12.3.3. Others

12.4. Market Value Forecast, by Route of Administration, 2018–2027

12.4.1. Oral/Buccal

12.4.2. Rectal

12.4.3. Nasal

12.4.4. Parenteral

12.5. Market Value Forecast, by Distribution Channel, 2018–2027

12.5.1. Hospital Pharmacies

12.5.2. Retail Pharmacies

12.5.3. Online Pharmacies

12.6. Market Value Forecast, by Country/Sub-region, 2018–2027

12.6.1. Germany

12.6.2. U.K.

12.6.3. France

12.6.4. Spain

12.6.5. Italy

12.6.6. Rest of Europe

12.7. Market Attractiveness Analysis

12.7.1. By Therapeutics

12.7.2. By Type

12.7.3. By Route of Administration

12.7.4. By Distribution Channel

12.7.5. By Country/Sub-region

13. Asia Pacific Epileptic Seizures Treatment Market Analysis and Forecast

13.1. Introduction

13.1.1. Key Findings

13.2. Market Value Forecast, by Therapeutics, 2018–2027

13.2.1. Midazolam

13.2.2. Alprazolam

13.2.3. Diazepam

13.2.4. Lorazepam

13.2.5. Phenytoin

13.2.6. Fosphenytoin

13.2.7. Others

13.3. Market Value Forecast, by Type, 2018–2027

13.3.1. Repetitive Seizures

13.3.2. Status Epilepticus

13.3.2.1. Convulsive Status Epilepticus

13.3.2.2. Non-convulsive Status Epilepticus

13.3.3. Others

13.4. Market Value Forecast, by Route of Administration, 2018–2027

13.4.1. Oral/Buccal

13.4.2. Rectal

13.4.3. Nasal

13.4.4. Parenteral

13.5. Market Value Forecast, by Distribution Channel, 2018–2027

13.5.1. Hospital Pharmacies

13.5.2. Retail Pharmacies

13.5.3. Online Pharmacies

13.6. Market Value Forecast, by Country/Sub-region, 2018–2027

13.6.1. China

13.6.2. Japan

13.6.3. India

13.6.4. Australia & New Zealand

13.6.5. Rest of Asia Pacific

13.7. Market Attractiveness Analysis

13.7.1. By Therapeutics

13.7.2. By Type

13.7.3. By Route of Administration

13.7.4. By Distribution Channel

13.7.5. By Country/Sub-region

14. Latin America Epileptic Seizures Treatment Market Analysis and Forecast

14.1. Introduction

14.1.1. Key Findings

14.2. Market Value Forecast, by Therapeutics, 2018–2027

14.2.1. Midazolam

14.2.2. Alprazolam

14.2.3. Diazepam

14.2.4. Lorazepam

14.2.5. Phenytoin

14.2.6. Fosphenytoin

14.2.7. Others

14.3. Market Value Forecast, by Type, 2018–2027

14.3.1. Repetitive Seizures

14.3.2. Status Epilepticus

14.3.2.1. Convulsive Status Epilepticus

14.3.2.2. Non-convulsive Status Epilepticus

14.3.3. Others

14.4. Market Value Forecast, by Route of Administration, 2018–2027

14.4.1. Oral/Buccal

14.4.2. Rectal

14.4.3. Nasal

14.4.4. Parenteral

14.5. Market Value Forecast, by Distribution Channel, 2018–2027

14.5.1. Hospital Pharmacies

14.5.2. Retail Pharmacies

14.5.3. Online Pharmacies

14.6. Market Value Forecast, by Country/Sub-region, 2018–2027

14.6.1. Brazil

14.6.2. Mexico

14.6.3. Rest of Latin America

14.7. Market Attractiveness Analysis

14.7.1. By Therapeutics

14.7.2. By Type

14.7.3. By Route of Administration

14.7.4. By Distribution Channel

14.7.5. By Country/Sub-region

15. Middle East & Africa Epileptic Seizures Treatment Market Analysis and Forecast

15.1. Introduction

15.1.1. Key Findings

15.2. Market Value Forecast, by Therapeutics, 2018–2027

15.2.1. Midazolam

15.2.2. Alprazolam

15.2.3. Diazepam

15.2.4. Lorazepam

15.2.5. Phenytoin

15.2.6. Fosphenytoin

15.2.7. Others

15.3. Market Value Forecast, by Type, 2018–2027

15.3.1. Repetitive Seizures

15.3.2. Status Epilepticus

15.3.2.1. Convulsive Status Epilepticus

15.3.2.2. Non-convulsive Status Epilepticus

15.3.3. Others

15.4. Market Value Forecast, by Route of Administration, 2018–2027

15.4.1. Oral/Buccal

15.4.2. Rectal

15.4.3. Nasal

15.4.4. Parenteral

15.5. Market Value Forecast, by Distribution Channel, 2018–2027

15.5.1. Hospital Pharmacies

15.5.2. Retail Pharmacies

15.5.3. Online Pharmacies

15.6. Market Value Forecast, by Country/Sub-region, 2018–2027

15.6.1. GCC Countries

15.6.2. South Africa

15.6.3. Rest of Middle East & Africa

15.7. Market Attractiveness Analysis

15.7.1. By Therapeutics

15.7.2. By Type

15.7.3. By Route of Administration

15.7.4. By Distribution Channel

15.7.5. By Country/Sub-region

16. Competition Landscape

16.1. Market Player - Competition Matrix (by tier and size of companies)

16.2. Market Share/Position Analysis, by Company, 2019

16.3. Competitive Business Strategies

16.4. Company Profiles

16.4.1.Bausch Health Companies, Inc.

16.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)

16.4.1.2. Company Financials

16.4.1.3. Growth Strategies

16.4.1.4. SWOT Analysis

16.4.2.GlaxoSmithKline plc.

16.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)

16.4.2.2. Company Financials

16.4.2.3. Growth Strategies

16.4.2.4. SWOT Analysis

16.4.3.UCB S.A.

16.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)

16.4.3.2. Company Financials

16.4.3.3. Growth Strategies

16.4.3.4. SWOT Analysis

16.4.4. Pfizer, Inc.

16.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)

16.4.4.2. Company Financials

16.4.4.3. Growth Strategies

16.4.4.4. SWOT Analysis

16.4.5.Apotex, Inc.

16.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)

16.4.5.2. Company Financials

16.4.5.3. Growth Strategies

16.4.5.4. SWOT Analysis

16.4.6.Alexza Pharmaceuticals, Inc.

16.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)

16.4.6.2. Company Financials

16.4.6.3. Growth Strategies

16.4.6.4. SWOT Analysis

16.4.7. Neurelis, Inc.

16.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)

16.4.7.2. Company Financials

16.4.7.3. Growth Strategies

16.4.7.4. SWOT Analysis

16.4.8.Veriton Pharma

16.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)

16.4.8.2. Company Financials

16.4.8.3. Growth Strategies

16.4.8.4. SWOT Analysis

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers